Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular Degeneration

Blodi, B., A. Domalpally, E. Corkery, A. Osborne, S. Blotner, S. Grzeschik, and S. Gune. Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab Versus Sham for Neovascular Age-Related Macular Degeneration. Ophthalmol Retina, 2023, p. Epub PubMed Text.

Abstract

Objective: Determine prevalence, progression rates, and associations of newly detectable macular atrophy (MA) in patients with choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD) with/without ranibizumab treatment.

Keywords: Macular atrophy; Neovascular age-related macular degeneration; Ranibizumab.